Compare Peptides Side by Side

Put any two or three of the 85 library entries next to each other on compound class, molecular weight, half-life, origin, mechanism and studied research areas — the attributes that actually distinguish one compound from another.

BPC-157 vs TB-500 Semaglutide vs Tirzepatide vs Retatrutide Sermorelin vs CJC-1295 vs Ipamorelin Selank vs Semax GHK-Cu vs AHK-Cu Ipamorelin vs Hexarelin vs GHRP-2

Compound A Compound B Compound C optional

Side-by-side comparison of BPC-157, TB-500 on compound class, molecular weight, half-life, origin, mechanism and studied research areas.
Attribute	BPC-157	TB-500
Compound class	Synthetic pentadecapeptide	N-terminally acetylated thymosin beta-4 fragment
Research category	Healing & Recovery	Healing & Recovery
Length (amino acids)	15	7
Molecular weight	1419.5 Da	Not documented
Half-life	<30 minutes (elimination, reported in rats/dogs)	Not documented
Origin	BPC-157 is a synthetic peptide whose sequence corresponds to a partial fragment of human body protection compound (BPC), a protein reported to be present in gastric juice. It does not occur naturally as an isolated peptide and is produced synthetically for research.	In a 2012 analytical study (PMID 22962027), the tested TB-500 formulation contained Ac-LKKTETQ, the N-terminally acetylated seven-residue 17-23 fragment of human thymosin beta-4. This fragment is chemically distinct from the full-length 43-amino-acid parent protein. The study identifies the tested material, not every product sold under the TB-500 name.
Mechanism	In animal and in-vitro studies, BPC-157 has been associated with promotion of angiogenesis and modulation of growth-factor signaling pathways, including effects reported on the VEGFR2 pathway and nitric oxide systems. Researchers have also described interactions with the FAK-paxillin pathway and effects on fibroblast and tendon-cell migration. These mechanisms are characterized primarily in rodent models and cell culture and have not been established in controlled human trials.	The LKKTETQ sequence corresponds to the actin-binding region of thymosin beta-4. Research on the parent protein and related fragments examines actin regulation, cell migration and wound repair. Those findings must be tied to the exact molecule tested; they do not establish that acetylated Ac-LKKTETQ has all the effects of full-length thymosin beta-4.
Research areas	Tendon, ligament and muscle healing (animal models) Gastrointestinal mucosal protection and ulcer healing (rodent studies) Angiogenesis and wound healing (preclinical) Nerve and bone injury repair (animal models) Modulation of NSAID-related gastrointestinal injury (rodent studies)	Analytical identification of Ac-LKKTETQ in a TB-500 formulation Actin-binding domain research involving related thymosin beta-4 sequences Wound repair in mouse studies of the parent protein and the non-acetylated LKKTETQ peptide
What sets it apart	BPC-157 is a 15-amino-acid synthetic peptide investigated in animal and cell models. TB-500 is associated with a different, acetylated fragment of thymosin beta-4; a difference in proposed mechanisms does not establish that combining them improves outcomes.	The defining distinction is molecular identity: the analyzed TB-500 formulation contained Ac-LKKTETQ, whereas full-length thymosin beta-4 contains 43 residues. BPC-157 is a separate synthetic 15-residue peptide. Comparing these profiles does not establish a combination benefit.

Every compound you can compare

All 85 library entries. The pickers above hold the same list; these are direct links to each full entry.

Every published comparison

125 written head-to-head pages, one for each pairing the library already documents as co-studied. Each sets the two compounds against each other on class, mass, half-life, origin, mechanism and shared research areas.

Reading a peptide comparison

Compound class is the most useful first filter — a GHRH analog and a ghrelin-receptor agonist both sit in growth-axis research, but they act on different receptors and are studied for different reasons. Two compounds in the same category are not interchangeable.

Half-life determines how a compound behaves over time in a study design, and it varies enormously: some research peptides clear in minutes, others persist for days. It is the single largest driver of protocol differences between otherwise similar compounds.

Molecular weight and length indicate whether a compound is a short synthetic fragment or a larger protein-like molecule, which in turn affects stability, storage, and how it is handled in the lab.

Origin distinguishes naturally occurring sequences from synthetic analogs designed to modify half-life, receptor selectivity, or stability relative to the parent molecule.

Deeper comparisons

For narrative comparisons with the underlying research context rather than a specification table:

BPC-157 vs TB-500 — the two most commonly stacked tissue-repair peptides.
Sermorelin vs CJC-1295 — two GHRH analogs with very different half-lives.
Selank vs Semax — two short synthetic peptides in nootropic research.
GLP-1 family comparison — mono-, dual- and triple-agonist compounds.